Clinical trials: Cervical Cancer by FIGO Stage 2018
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the…
- Conditions
- Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT04574635
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Cervical Cancer
Para Aortic Lymphadenectomy : Always ?
Cervical cancer affects more than 3000 new cases per year in France. The treatment of stage IB3 to IVA cervical cancer is based on concomitant radio-chemotherapy.
- Trial name
- PALA (NCT04392895)
- Testing
- Para Aortic Lymphadenectomy (PAL) by laparoscopy
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Montpellier
Cervical Cancer by FIGO Stage 2018
Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers
Cervical cancer is the fourth most common cancer among women and is mainly linked to infection with high-risk human papillomaviruses (HPV).
- Trial name
- RETHEMCOL (NCT07461142)
- Testing
- radiotherapy with bone marrow contouring
- Volunteers
- 72 people
- Sponsor
- Institut Paoli-Calmettes
Uterine Cervical Neoplasms, Chemoradiotherapy
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy.
- Conditions
- Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant Chemotherapy
- Trial name
- NCT05735145
- Testing
- paclitaxel combined with platinum
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
Cervical Cancer
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment.
- Trial name
- NCT04016389
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- 4 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- University Health Network, Toronto
Cervical Cancer, Neoadjuvant Therapy
QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of QL1706 combined with cisplatin and paclitaxel as neoadjuvant therapy in patients with FIGO 2018 stage IB1-IB3 cervical…
- Conditions
- Cervical Cancer, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT07617818
- Testing
- QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Uterine Cervical Neoplasms, Cervical Cancer by FIGO Stage 2018
A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer
Cervical cancer is the fourth most common cancer in women worldwide, with approximately 604,000 new cases in 2020.Treatment for locally advanced cervical cancer is based on a combination of radiotherapy and chemotherapy.
- Trial name
- EPICOL-R (NCT07305727)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Uterine Cervical Neoplasms, Sintilimab
A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer
This is a single-arm, single-center phase II clinical study to explore the efficacy and safety of sintilimab combined with concurrent chemoradiation therapy as treatment in women with locally advanced cervical cancer.
- Trial name
- NCT05105672
- Testing
- Sintilimab, Cisplatin, External Beam Radiotherapy (EBRT)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
This phase II trial studies how well time-restricted eating works in reducing side effects of radiation or chemoradiation side effects when compared to nutritional counseling among patients with prostate, cervical, and rectal…
- Conditions
- Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05722288
- Testing
- Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- City of Hope Medical Center
Neoadjuvant Immunotherapy, Cervical Cancer
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
This is a Phase II study of neoadjuvant therapy of AK104 combined with nab-paclitaxel/carboplatin in fertility saving surgery for stage IB2-IB3 cervical cancer (FIGO 2018).
- Conditions
- Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery
- Trial name
- NCT06209294
- Testing
- AK104, Carboplatin, Nab paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiaohua Wu
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the…
- Conditions
- Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018
- Trial name
- NCT07061977
- Testing
- Biospecimen Collection, Brachytherapy, Carboplatin
- Where
- 346 sites in United States, Puerto Rico
- Volunteers
- 336 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer by FIGO Stage 2018
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity…
- Trial name
- ARTIA-Cervix (NCT05197881)
- Testing
- Varian Ethos Adaptive Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 125 people
- Sponsor
- Varian, a Siemens Healthineers Company
Stage IV Cervical Cancer FIGO 2018, Adenosquamous Carcinoma of Cervix
Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer
To improve overall survival in patients with metastatic cervical cancer by loco-regional therapy with personalized ultra-fractionated radiation
- Conditions
- Stage IV Cervical Cancer FIGO 2018, Adenosquamous Carcinoma of Cervix, Cervical Cancer, Metastasis
- Trial name
- NCT05021237
- Testing
- Ultra-fractionated radiation therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Texas Southwestern Medical Center
Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
The goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy.
- Conditions
- Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
- Trial name
- NCT07368985
- Testing
- pembrolizumab and lenvatinib
- Where
- Netherlands
- Volunteers
- 87 people
- Sponsor
- Prof. Dr. Remi A. Nout